MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Serum Metabolomics in Parkinson’s Disease: Correlations with Fecal Microbiome, Fecal Metabolomics and Clinical Status

TS. Toh, CW. Chong, MF. Loke, JW. Hor, LC. Lit, J. Bowman, SL. Song, CSJ. Teh, S-Y. Lim, AH. Tan (Kuala Lumpur, Malaysia)

Meeting: 2023 International Congress

Abstract Number: 1296

Keywords: Parkinson’s

Category: Parkinson's Disease: Pathophysiology

Objective: To investigate the correlations between serum metabolites with fecal microbiome, fecal metabolites, and clinical phenotypes in patients with Parkinson’s disease (PD).

Background: There is accumulating evidence showing altered gut microbial composition and metabolism in PD patients [1,2,3,4]. However, the impact of these gut changes on host metabolism, and vice versa, remains unclear.

Method: 67 PD patients and 64 non-PD controls were extensively phenotyped. Fecal and serum metabolomics were performed using liquid chromatography-mass spectrometry, while fecal microbiome was analysed using 16S rRNA gene sequencing. Multivariate analyses with false discovery rate (FDR) corrections were used to analyze between-group differences and correlations in this clinico-biological meta-dataset.

Results: Of the 473 filtered serum metabolites, we found 46 differentially abundant metabolites in patients vs. controls. These include alterations in lipids (especially fatty acyls, sterol lipids and glycerophospholipids), amino acids and organic compounds (including xenobiotics from pesticides, chemical solvents, drugs, food constituents, and natural products) [figure1]. Predictive functional analyses revealed consistent results — 23 pathways were altered in PD, with most of them involving metabolism of amino acids, lipids, hormones, vitamins and xenobiotics. Multivariate correlation analyses in the PD subgroup revealed associations between several serum and fecal fatty acids and phospholipids, as well as serum amino acid derivatives and specific gut microbes. Notably, the intercorrelated network of alanine, glutamic acid, pencycuron and phenylalanine in serum correlated with several fecal metabolites, microbial features and constipation severity in PD. Among the metabolites greatly reduced in PD (>9 log2 fold change), lower levels of 2-aminomethylpyrimidine correlated with worse Hoehn and Yahr staging, and is involved in the dipeptidyl peptidase-4 and glucagon-like peptide-1 pathway, believed to be neuroprotective in PD [5].

Conclusion: This multi-omics study revealed significant alterations in serum metabolome profiles of PD patients, and new insights concerning associations between host metabolites with gut metabolism, as well as with disease severity. Further studies are warranted to examine the role of these metabolites in PD pathophysiology.

Figure 1

References: [1] Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease – from basic research to the clinic. Nat Rev Neurol. 2022;18(8):476-495.
[2] Tan AH, Chong CW, Lim SY, Yap IKS, Teh CSJ, Loke MF, Song SL, Tan JY, Ang BH, Tan YQ, Kho MT, Bowman J, Mahadeva S, Yong HS, Lang AE. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol. 2021;89(3):546-559.
[3] Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR, Payami H. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun. 2022;13(1):6958.
[4] Chen SJ, Chen CC, Liao HY, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Alteration of gut microbial metabolites in the systemic circulation of patients with Parkinson’s disease. J Parkinsons Dis. 2022;12(4):1219-1230.
[5] Bomba M, Granzotto A, Castelli V, Massetti N, Silvestri E, Canzoniero LMT, Cimini A, Sensi SL. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging. 2018;64:33-43.

To cite this abstract in AMA style:

TS. Toh, CW. Chong, MF. Loke, JW. Hor, LC. Lit, J. Bowman, SL. Song, CSJ. Teh, S-Y. Lim, AH. Tan. Serum Metabolomics in Parkinson’s Disease: Correlations with Fecal Microbiome, Fecal Metabolomics and Clinical Status [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/serum-metabolomics-in-parkinsons-disease-correlations-with-fecal-microbiome-fecal-metabolomics-and-clinical-status/. Accessed September 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/serum-metabolomics-in-parkinsons-disease-correlations-with-fecal-microbiome-fecal-metabolomics-and-clinical-status/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley